Intellia Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology. Its programs focus on in vivo editing delivered systemically, aiming to treat genetic diseases such as transthyretin amyloidosis and hereditary angioedema with one-time or durable therapies. The company is a clinical-stage biotech whose platform is designed to permanently modify disease-causing genes inside the body rather than only editing cells outside the patient.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 16.6 | — | -114.3 | — |
| Q2 2025 | 14.2 | — | -101.3 | — |
| Q3 2025 | 13.8 | — | -101.3 | — |
| Q4 2025 | 23 | — | -95.8 | — |
| Q1 2026 | 15.1 | -9.5% | -96.2 | — |
| Q2 2026 | 7.7 | -46.2% | -106.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Anterix Inc. (ATEX), Septerna, Inc. (SEPN), Hope Bancorp, Inc. (HOPE), FirstSun Capital Bancorp (FSUN), Fortrea Holdings Inc. (FTRE), S&T Bancorp, Inc. (STBA)